As­traZeneca her­alds Tagris­so's OS lead over old TKIs in lung can­cer niche

BARCELONA — As­traZeneca is draw­ing the cur­tains on just how much longer Tagris­so can help non-small cell lung can­cer pa­tients live com­pared to first-gen­er­a­tion ty­ro­sine ki­nase in­hibitors tar­get­ing the EGFR mu­ta­tion, mak­ing a strong case for its front­line use in this niche.

Hav­ing pre­vi­ous­ly scored on the pri­ma­ry end­point of PFS, the phar­ma gi­ant is spelling out the OS da­ta at ES­MO Con­gress 2019: 38.6 months with Tagris­so ver­sus 31.8 months on Tarce­va or Ires­sa, giv­ing rise to a haz­ard ra­tio of 0.799 (p=0.0462).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER